Advanced Cell's lawsuit took a bigger toll than expected, might be a good time for Lanza to CEO ReCyte and the merger to finally happen.....ACTC investors at this point couldn't be more disappointed!
Biotime already has Gerons hESC ip, having ACTC's ips ip would as in Dr. Wests words make Biotime "The complete consolidation of the stem cell industry".
Well they just got 14 mil from CIRM who seems to believe they have the technology with "the best chance for success"......and the big pharma like TEVA looks like they will likely have exclusively license Biotimes AMD product and therefore pay 100% of trials and marketing, so I think they word is spreading that btx has cutting edge, best in class ip and will dominate the market.
Look for more major partnerships, and of course for their stock to triple within 6 months....IMO
msft... Nonsense. ACTC's Lanza is still referenced as the actual doer of real state of the art in "regenerative medicine"--and has now passed peer review for serious breakthru in SCNT. Of course that has nothin at all to do with the common stock--chicken poop bingo---anymore than any "science" BTX is doing has to do woth its common stock.
Thr lawsuit took a far smaller toll than some expected---the stock was not halted and nobody went to prison. It was just a $4mm fine for years of exactly the same kind of book-keeping that AK has BTX doing.
Would be acquisition #7:
1-Cell Targeting for cancer IP(now OrthoCyte)
3-ESI for gold standard GMP hesc lines
4-Gene Cards(now LifeMap) for biological databases
5-Cell Cure for neural and retinal stem IP
6-Geron for 600 patents including hesc, telomere and cancer vaccine IP
BTX now has 109 employees, no debt, 7 subsidiaries, largest stem cell ip in the world(600+), a strangle hold on hESC's(THE gold standard), most searched database in the world for biological reagents.....clearly the words leader at this point and all for a LOW LOW price of $2.80....obviously looking at a quadruple by mid next year.